Synthesis and modeling studies with monocyclic analogues of mycophenolic acid

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 46-55

  Anderson, Wayne K ^a   Boehm, Terri L ^a   Makara, Gergely M ^a   Swann, R Thomas ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG SYNTHESIS; HYDROGEN BOND; MOLECULAR MODEL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; HUMANS; HYDROGEN BONDING; IMP DEHYDROGENASE; LEUKEMIA L1210; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MYCOPHENOLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030026393     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9501339     Document Type: Article

References (76)

1. Antonino, L. C.; Wu, J. C. Human IMP Dehydrogenase Catalyzes the Dehalogenation of 2-Fluoro- and 2-Chloroinosine 5′-Monophosphate in the Absence of NAD. Biochemistry 1994, 33, 1753-1759.
2. (a) Jones, W.; Wolfenden, R. How Rare are the Covalent Hydrates of Purine Ribonucleoside and Nicotinamide? A Method for Estimating Positions of Highly Unfavorable Equilibria. J. Am. Chem. Soc. 1986, 108, 7444-7445.
3. (b) Wolfenden, R.; Kati, W. M. Testing the Limits of Protein-Ligand Binding Discrimination with Transition-State Analogue Inhibitors. Acc. Chem. Res. 1991, 24, 209-215.
4. (a) Smee, D. F.; Gilbert, J.; Leonhardt, J. A.; Barnett, B. B.; Huggins, J. H.; Sidwell, R. W. Treatment of Lethal Pichinde Virus Infections in Weanling LVG/Lak Hamsters with Ribavirin, Ribamidine, Selenazofurin, and Ampligen. Antiviral Res. 1993, 20, 57-70.
5. (b) Liao, H. J.; Stollar, V. Reversal of the Antiviral Activity of Ribavirin Against Sindbis Virus in Aedes Albopictus Mosquito Cells. Antiviral Res. 1993, 22, 285-294.
6. (c) De Clercq, E. Antiviral Agents: Characteristic Activity Spectrum Depending on the Molecular Target with Which They Interact. Adv. Virus Res. 1993, 42, 1-55.
7. (d) Canonico, P. G.; Kende, M.; Luscri, B. J.; Huggins, J. W. In-Vivo Activity of Antivirals Against Exotic RNA Viral Infections. J. Antimicrob. Chemother. 1984, 14 (Suppl. A) 27-41.
8. (e) Huggins, J. W.; Robins, R. K.; Canonico, P. G. Synergistic Antiviral Effects of Ribavirin and The C-Nucleoside Analogs Tiazofurin and Selenazofurin Against Togaviruses, Bunyaviruses, and Arenaviruses. Antimicrob. Agents Chemother. 1984, 26, 476-480.
9. (f) Kirsi, J. J.; McKernan, P. A.; Burns, N. J.; North, J. A.; Murray, B. K.; Robins, R. K. Broad-Spectrum Synergistic Antiviral Activity of Selenazofurin and Ribavirin. Antimicrob. Agents Chemother. 1984, 26, 466-475.
10. (g) Malinoski, F.; Stollar, V. Inhibitors of IMP Dehydrogenase Prevent Sindbis Virus Replication and Reduce GTP Levels in Aedes Albopictus Cells. Virology 1981, 110, 281-289.
11. Newman, E. M.; Spallone, P. A.; Zaia, J. A.; Khwaja, T. A.; Robins, R. K. Activity of Inosine Monophosphate Dehydrogenase Inhibitors Against Human Immunodeficiency Virus (Meeting Abstract). Proc. Am. Assoc Cancer Res. 1987, 28, 323.
12. Weber, G.; Hata, Y.; Prajda, N. Role of Differentiation Induction in Action of Purine Antimetabolites. Pharm. World Sci. 1994, 16, 77-83.
13. (a) Agbaria, R.; Mullen, C. A., Hartman, N. R.; Cooney, D. A.; Hao, Z.; Blaese, R. M.; Johns, D. G. Effects of IMP Dehydrogenase Inhibitors on the Phosphorylation of Gancyclovir in Molt-4 Cells Before and After Herpes Simplex Virus Thymidine Kinase Gene Transduction. Mol. Pharmacol. 1994, 45, 777-782.
14. (b) Hartman, N. R.; Ahluwalia, G. S.; Cooney, D. A.; Mitsuya, H.; Kageyama, S.; Fridland, A.; Broder, S.; Johns, D. G. Inhibitors of IMP Dehydrogenase Stimulate the Phosphorylation of the Anti-Human Immunodeficiency Virus Nucleosides 2′,3′-Dideoxyadenosine and 2′,3′-Dideoxyinosine. Mol. Pharmacol. 1991, 40, 118-124.
15. (a) Yamada, Y.; Natsumeda, Y.; Weber, G. Action of the Active Metabolites of Tiazofurin and Ribavirin on Purified IMP Dehydrogenase. Biochemistry 1988, 27, 2193-2196.
16. (b) Lee, H.-J.; Pawlak, K.; Nguyen, B. T.; Robins, R. K.; Sadee, W. Biochemical Differences Among Four Inosinate Dehydrogenase Inhibitors, Mycophenolic Acid, Ribavirin, Tiazofurin, and Selenazofurin, Studied in Mouse Lymphoma Cell Culture. Cancer Res. 1985, 45, 5512-5520.
17. (c) Gebeyehu, G.; Marquez, V. E.; Van Cott, A.; Cooney, D. A.; Kelley, J. A.; Jayaram, H. N.; Ahluwalia, G. S.; Dion, R. L.; Wilson, Y. A.; Johns, D. G. Ribavirin, Tiazofurin, and Selenazofurin: Mononucleotides and Nicotinamide Adenine Dinucleotide Analogues. Synthesis, Structure, and Interactions with IMP Dehydrogenase. J. Med. Chem. 1985, 28, 99-105.
18. (a) Carr; S. F.; Papp, E.; Wu, J. C.; Natsumeda, Y. Characterization of Human Type-I and Type-II IMP Dehydrogenases. J. Biol. Chem. 1993, 268, 27286-27290.
19. (b) Dayton, J. S.; Lindsten, T.; Thompson, C. B.; Mitchell, B. S. Effects of Human T-Lymphocyte Activation on Inosine Monophosphate Dehydrogenase Expression. J. Immunol. 1994, 152, 984-991.
20. (a) Konno, Y.; Natsumeda, Y.; Nagai, M.; Yamaji, Y.; Ohno, S.; Suzuki, K.; Weber, G. Expression of Human IMP Dehydrogenase Types I and II in Escherichia Coli and Distribution in Human Normal Lymphocytes and Leukemic Cell Lines. J. Biol. Chem. 1991, 266, 506-509.
21. (b) Nagai, M.; Natsumeda, Y.; Konno, Y.; Hoffman, R.; Irino, S.; Weber, G. Selective Up-Regulation of Type II Inosine 5′-Monophosphate Dehydrogenase Messenger RNA Expression in Human Leukemias. Cancer Res. 1991, 51, 3886-3890.
22. (c) Natsumeda, Y.; Ohno, S.; Kawasaki, H.; Konno, Y.; Weber, G.; Suzuki, K. Two Distinct CDNAs for Human IMP Dehydrogenase. J. Biol. Chem. 1990, 265, 5292-5295.
23. (a) Stet, E. H.; De Abreu, R. A.; Janssen, Y. P.; Bokkerink, J. P.; Trijbels, F. J. A Biochemical Basis for Synergism of 6-Mercaptopurine and Mycophenolic Acid in Molt F4, a Human Malignant T-Lymphoblastic Cell Line. Biochim. Biophys. Acta 1993, 1180, 277-282.
24. (b) Stet, E. H.; Deabreu, R. A.; Bokkerink, J. P. M.; Lambooy, L. H. J.; Vogelsmentink, T. M.; Trijbels, F. J. M. Inhibition of IMP Dehydrogenase by Mycophenolic Acid in Molt F4 Human Malignant Lymphoblasts. Ann Clin. Biochem. 1994, 31, 174-180.
25. (c) Wilson, B. S.; Deanin, G. G.; Standefer, J. C.; Vanderjagt, D.; Oliver, J. M. Depletion of Guanine Nucleotides with Mycophenolic Acid Suppresses Ige Receptor-Mediated Degranulation in Rat Basophilic Leukemia Cells. J. Immunol. 1989, 143, 259-265.
26. (d) Mitsui, A.; Matsuno, T,; Ogawa, H.; Shiio, T.; Yugari, Y.; Tamura, G. Antitumor Activity of a New Compound, Ethyl O-[N-(P-Carboxyphenyl)-carbamoyl]-mycophenolate, Against Various Experimental Tumors Upon Oral Administration. Gann 1981, 72, 66-71.
27. (e) Bates, T. A Preliminary Clinical Study of the Use of Mycophenolic Acid as a Radiosensitizer. Eur. J. Cancer 1977, 13, 475-477.
28. (f) Suzuki, S.; Mori, T. Carbamoyl Mycophenolic Acid Ethylester, an Oral Antitumor Agent. J. Antibiot. 1976, 29, 286-291.
29. (g) Suzuki, S.; Takaku, S.; Mori, T. Antitumor Activity of Derivatives of Mycophenolic Acid. J. Antibiot. 1976, 29, 275-285.
30. (h) Connolly, J. G.; Halsall, G. M. Use of Mycophenolic Acid in Superficial Bladder Cancer. Urology 1975, 5, 131-132.
31. (i) Knudtzon, S.; Nissen, N. I. Clinical Trial with Mycophenolic Acid (NSC-129185), a New Antitumor Agent. Cancer Chemother. Rep. Part 1 1972, 56, 221-227.
32. (j) Sweeney, M. J.; Gerzon, K.; Harris, P. N.; Holmes, R. E.; Poore, G. A.; Williams, R. H. Experimental Antitumor Activity and Preclinical Toxicology of Mycophenolic Acid. Cancer Res. 1972, 32, 1795-1802.
33. (k) Sweeney, M. J.; Hoffman, D. H.; Poore, G. A. Possible In Situ Activation of Mycophenolic Acid by Beta-Glucuronidase. Cancer Res. 1971, 32, 477-478.
34. (m) Suzuki, S.; Kimura, T.; Ando, K.; Sawada, M.; Tamura, G. Antitumor Activity of Mycophenolic Acid. J. Antibiot. 1969, 22, 297-302.
35. (a) Berman, J. D.; Webster, H. K. In Vitro Effects of Mycophenolic Acid and Allopurinol Against Leishmania Tropica in Human Macrophages. Antimicrob. Agents Chemother. 1982, 21, 887-891.
36. (b) Verham, R.; Meek, T. D.; Hedstrom, L.; Wang, C. C. Purification, Characterization, and Kinetic Analysis of Inosine 5′-Monophosphate Dehydrogenase of Tritrichomonas Foetus. Mol. Biochem. Parasitol. 1987, 24, 1-12.
37. (c) Noto, T.; Sawada, M.; Ando, K.; Koyama, K. Some Biological Properties of Mycophenolic Acid. J. Antibiot. 1969, 22, 165-169.
38. (a) Alfieri, C.; Allison, A. C.; Kieff, E. Effect of Mycophenolic Acid on Epstein-Barr Virus Infection of Human B-Lymphocytes. Antimicrob. Agents Chemother. 1994, 38, 126-129.
39. (b) Cline, J. C.; Nelson, J. D.; Gerzon, K.; Williams, R. H.; DeLong, D. C. In Vitro Antiviral Activity of Mycophenolic Acid and Its Reversal by Guanine-Type Compounds. Appl. Microbiol. 1969, 18, 14-20.
40. (c) Planterose, D. N. Antiviral and Cytotoxic Effects of Mycophenolic Acid. J. Gen. Virol. 1969, 4, 629-630.
41. (d) Williams, R. H.; Lively, D. H.; DeLong, D. C.; Cline, J. C.; Sweeny, M. J. Mycophenolic Acid: Antiviral and Antitumor Properties. J. Antibiot. 1968, 21, 463-464.
42. (a) Allison, A. C.; Eugui, E. M. Mycophenolate Mofetyl, a Rationally Designed Immunosuppressive Drug. Clin. Transplant. 1993, 7, 96-112.
43. (b) Allison, A. C.; Eugui, E. M. Immunosuppressive and Other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetyl. Immunol. Rev. 1993, 136, 5-28.
44. (a) Gomez, E. C.; Menendez, L.; Frost, P. Efficacy of Mycophenolic Acid for the Treatment of Psoriasis. J. Am. Acad. Dermatol. 1979, 1, 531-537.
45. (b) Sweeney, M. J. Mycophenolic Acid and Its Mechanism of Action in Cancer and Psoriasis. J. Antibiot. 1977, 30S, 85-92.
46. (c) Marinari, R.; Fleischmajer, R.; Schragger, A. H.; Rosenthal, A. L. Mycophenolic Acid in the Treatment of Psoriasis: Long-Term Administration. Arch. Dermatol. 1977, 113, 930-932.
47. (d) Lynch, W. S.; Roenigk, H. H., Jr. Mycophenolic Acid for Psoriasis. Arch. Dermatol. 1977, 113, 1203-1208.
48. (a) Ando, K.; Suzuki, S.; Arita, M. Synthesis of Mycophenolic Acid Beta-D-Glucuronide and Its Antitumor Activity. J. Antibiot. 1970, 23, 408-413.
49. (b) Nery, R.; Nice, E. The Metabolism and Binding of (14 C)Mycophenolic Acid in the Rat. J. Pharm. Pharmacol. 1971, 23, 842-847.
50. (c) Sweeney, M. J.; Hoffman, D. H.; Esterman, M. A. Metabolism and Biochemistry of Mycophenolic Acid. Cancer Res. 1972, 32, 1803-1809.
51. (d) Bopp, R. J.; Schirmer, R. E.; Meyers, D. B. Determination of Mycophenolic Acid and Its Glucuronide Metabolite in Plasma. J. Pharm. Sci. 1972, 61, 1750-1753.
52. (e) Gomez, E. C.; Michaelover, J.; Frost, P. Cutaneous B-Glucuronidase: Cleavage of Mycophenolic Acid by Preparations of Mouse Skin. Br. J. Dermatol. 1977, 97, 306.
53. Lintrup, J.; Hyltoft-Petersen, P.; Knudtzon, S.; Nissen, N. I. Metabolic Studies in Man with Mycophenolic Acid (NSC-129185), a New Antitumor Agent. Cancer Chemother. Rep. Part 1 1972, 56, 229-235.
54. (a) Campbell, I. M.; Calzadilla, C. H.; McCorkindale, N. J. Some New Metabolites Related to Mycophenolic Acid. Tetrahedron Lett. 1966, 5107-5111.
55. (b) McCorkindale, N. J.; Baxter, R. L.; Turner, W. B. 4-Methyl- And 7-Methylphthalan-1-one Derivatives of Mycophenolic Acid. Use in Establishing the Distribution of Acetate Derived Hydrogens. Tetrahedron 1981, 37, 2131-2136.
56. (c) Abbott, B. J.; Horton, D. R.; Whitney, J. G. Glucosylation of Mycophenolic Acid by Streptomyces Aureofaciens. J. Antibiot. 1980, 33, 506-509.
57. (d) Carman, R. M. Derivatives of Mycophenolic Acid. Aust. J. Chem. 1978, 31, 353-364.
58. (e) Aragozzini, F.; Toppino, P.; Craveri, R.; Beretta, M. G.; Rindone, B.; Scolastico, C. Analogues of Mycophenolic Acid. Bioorg. Cfiem. 1975, 4, 127-131.
59. (f) Jones, D. F.; Moore, R. H.; Crawley, G. C. Microbial Modification of Mycophenolic Acid. J. Chem. Soc. C 1970, 1725-1737.
60. (g) Logan, W. R.; Newbold, G. T. Lactones: Part V. Experiments Relating to Mycophenolic Acid. J. Chem. Soc. 1957, 1946-1951.
61. Jones, D. F.; Mills, S. D. Preparation and Antitumor Properties of Analogs and Derivatives of Mycophenolic Acid. J. Med. Chem. 1971, 14, 305-311.
62. Beisler, J. A.; Hillery, S. S. Antitumor Agents II: Nitrogen Analogs of Mycophenolic Acid. J. Pharm. Sci. 1975, 64, 84-87.
63. Kawagishi, H.; Ando, M.; Mizuno, T. Hericenone A and B as Cytotoxic Principles from the Mushroom Hericium Erinaceum. Tetrahedron Lett. 1990, 31, 373-376.
64. Nelson, P. H.; Eugui, E.; Wang, C. C.; Allison, A. C. Synthesis and Immunosuppressive Activity of Some Side-Chain Variants of Mycophenolic Acid. J. Med. Chem. 1990, 33, 833-838.
65. Lee, J.; Anderson, W. K. A Facile Synthesis of an (E)-4-Methyl-4-Hexenoic Acid Substituted Pyridine Analogue of Mycophenolic Acid. Synth. Commun. 1992, 22, 369-376.
66. Birch, A. J.; Wright, J. J. A Total Synthesis of Mycophenolic Acid. Aust. J. Chem. 1969, 22, 2635-2644.
67. (a) Canonica, L.; Rindone, B.; Santaniello, E.; Scolastico, C. A Total Synthesis of Mycophenolic Acid. Some Analogues and Some Biogenetic Intermediates. Tetrahedron 1972, 28, 4395-4404.
68. (b) Danheiser, R. L.; Gee, S. K.; Perez, J. J. Total Synthesis of Mycophenolic Acid. J. Am. Chem. Soc. 1986, 108, 806-810.
69. (c) Patterson, J. W. The Synthesis of Mycophenolic Acid. Tetrahedron. 1993, 49, 4789-4798.
70. (a) Colombo, L.; Gennari, C.; Potenza, D.; Scolastico, C. (E,E)-10-(1,3-Dihydro-4,6-dihydroxy-7-methyl-3-oxoisobenzofuran-5-yl)-4,8- dimethyldeca-4,8-dienoic Acid: Total Synthesis and Role in Mycophenolic Acid Biosynthesis. J. Chem. Soc., Chem. Commun. 1979, 1021-1022.
71. (b) Auricchio, S.; Ricca, A.; de Pava, O. V. New Synthesis of 5,7-Dihydroxy-4-methylphtalide, a Key Intermediate in the Synthesis of Mycophenolic Acid. J. Org. Chem. 1983, 48, 602-604.
72. (c) Watanabe, M.; Tsukazaki, M.; Hamada, Y.; Iwao, M.; Furukawa, S. An Efficient Synthesis of Phthalides by Diels-Alder Reaction of Sulfur Substituted Furanones with Silyloxydienes-A Formal Synthesis of Mycophenolic Acid. Chem. Pharm. Bull. 1989, 37, 2948-2951.
73. (d) Kobayashi, K.; Shimizu, H.; Itoh, M.; Suginome, H. An Efficient Synthesis of 5,7-Dihydroxy-4-methylisobenzofuran-1(3H)-one, a Metabolite of Aspergillus Flavus and a Key Intermediate in the Synthesis of Mycophenolic Acid. Bull. Chem. Soc. Jpn. 1990, 63, 2435-2437.
74. 50 = 0.2-0.3 μM).
75. All calculations were performed by SYBYL 6.03 (Tripos Associates Inc.) with an interface to MOPAC 5.0 (QCPE no. 455).
76. Cresp, T. M.; Sargent, M. V.; Elia, J. A.; Murphy, D. P. H. Formylation and Bromination ortho to the Hydroxy-group of 2-Carbonyl-substituted Phenols in the Presence of Titanium (IV) Chloride. J. Chem. Soc. Perkin Trans. 1 1973, 340.